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Introduction {#sec1}
============

Stem cells have long been of interest to developmental biologists; however, these cells have now gained the interest of the broader scientific community because of their potential to repair degenerating tissues. For example, neural stem cells (NSCs) and the new neurons that they produce are now recognized as necessary for learning and memory, for promoting cognitive function, and for their potential to replace neurons and glial cells lost as a consequence of brain injury or disease ([@bib18], [@bib45], [@bib78]). Similarly, adult intestinal stem cells (ISCs), which reside at the bottom of the crypt of Lieberkühn, constantly replenish the epithelial sheet for a lifespan, contributing to tissue homeostasis as well as mucosal regeneration after injury ([@bib67]).

Stem cells naturally reside within specific niches where they receive local signals that maintain them in a primitive state. The niches for each adult stem cell population differ; thus, most of the factors that maintain tissue-specific stem cells exert local effects restricted to that niche. Only a limited number of juxtacrine or paracrine signaling factors have been identified that maintain stem cells residing in multiple niches; these include epidermal growth factor (EGF), Notch, Wnts, fibroblast growth factors (FGFs), Shh, and transforming growth factor β ([@bib43]).

Insulin-like growth factor II (IGF-II) is highly expressed in the embryo and is necessary for normal embryonic and fetal growth ([@bib4], [@bib20], [@bib46], [@bib56], [@bib63]). In contrast, IGF-II is downregulated in most adult tissues, with notable exceptions including the brain and the intestine. In the adult CNS, IGF-II is produced by the choroid plexus, leptomeninges, endothelial cells, and stem/progenitor cells in the hippocampal subgranular zone (SGZ) ([@bib9], [@bib12], [@bib25], [@bib49], [@bib50], [@bib65]). Due to production by the choroid plexus, IGF-II protein is found at high levels in the cerebral spinal fluid ([@bib10]). The sites of IGF-II expression place it in close proximity to the NSCs residing in the two major NSC niches: the subventricular zone (SVZ) of the lateral ventricle and the hippocampal SGZ. Moreover, although the *Igf2* gene is imprinted such that it is expressed only from the paternal allele in most tissues ([@bib21], [@bib24], [@bib29]), it is biallelically expressed in choroid plexus, leptomeninges, and brain endothelial cells ([@bib15], [@bib21], [@bib23], [@bib25]).

Based on the expression data and our earlier studies on SVZ-derived neurospheres ([@bib80], [@bib79]), we hypothesized that IGF-II might be an integral component of the NSC niche. More recently, two studies provided support for IGF-II function in regulating NSCs; however, these studies did not address the function of IGF-II from multiple sources in regulating the adult NSCs. [@bib9] demonstrated that *Igf2* mRNA is expressed by NSCs in the dentate gyrus (DG) but not by the NSCs in the SVZ. Thus, short hairpin RNA knockdown of *Igf2* mRNA reduced proliferation of DG NSCs but not SVZ NSCs. A second report by [@bib25] demonstrated that deleting *Igf2* systemically beginning embryonically reduced the number of label-retaining cells in the SVZ and SGZ *in vivo*. However, loss of *Igf2* embryonically significantly reduces prenatal brain growth, making it impossible to separate the function of IGF-II in maintaining adult NSCs from a function in establishing NSCs during development. This study further demonstrated that loss of *Igf2* from endothelial cells beginning embryonically partially compromises SVZ NSCs but has no effect on the SGZ NSC population ([@bib25]), thus raising the question as to whether IGF-II is essential for maintaining the NSCs in the adult hippocampus.

In the intestine, IGF-II is found in the colonic mucosa, and *Igf2* loss of imprinting (LOI) in Apc^min/+^ background increases crypt length ([@bib58]). However, no studies to date have established whether IGF-II is an essential niche stem cell factor in the adult intestine. Therefore, to address the functions of IGF-II in multiple adult stem cell niches, we designed experiments to remove *Igf2* in young adult mice and evaluate adult NSC and ISC maintenance.

Results {#sec2}
=======

Adult NSCs Require Sustained IGF-II Production {#sec2.1}
----------------------------------------------

To determine whether IGF-II is necessary for adult stem cell homeostasis, we mated floxed *Igf2* mice with a tamoxifen-inducible Rosa 26 CreER driver mouse line ([@bib3], [@bib33]) to generate littermates for experimental animals that were all *Igf2*^*fl/fl*^ and either Cre^+^ or Cre^−^. Administering tamoxifen over 5 consecutive days beginning at postnatal day 21 (p21) resulted in death of *Igf2* knockout (KO) mice (see below regarding this lethal phenotype); therefore, we administered tamoxifen (75 mg/kg) every 3 days for the studies on the CNS ([Figure 1](#fig1){ref-type="fig"}A). PCR analysis 2 weeks after tamoxifen administration showed a recombined band of the expected size indicating excision of exons 4--6 of the *Igf2* gene ([Figure 1](#fig1){ref-type="fig"}B). Consistent with these results, mRNA levels of *Igf2* in choroid plexus and hippocampus were reduced by 90% in heterozygous Cre (*Igf2*^*fl/fl*^*Cre*^+/−^) mice versus wild-type (WT) (*Igf2*^*fl/fl*^) ([Figures 1](#fig1){ref-type="fig"}C and 1D). Since *Igf2* mRNA levels were similarly reduced in mice heterozygous and homozygous for Cre ([Figure S1](#mmc1){ref-type="supplementary-material"}), heterozygous Cre mice were used for all *in vivo* studies to exclude possible Cre toxicity ([@bib64]). Luxol fast blue with H&E staining from adult mice 3 months after *Igf2* removal revealed no gross anatomical changes in the brain structures surrounding the SVZ or SGZ of the *Igf2*-inducible KO (iKO) mice ([Figures 1](#fig1){ref-type="fig"}E and 1F). Additionally, no differences were observed in organ weights of the heart, lung, liver, kidney, and spleen adjusted to total body weight for WT and iKO mice (data not shown).Figure 1Tamoxifen-Induced Removal of *Igf2*Schematic for tamoxifen dosing in C57BL/6 mice (A). PCR for the floxed *Igf2* allele at 449 bp in iKO mice (*Igf2*^fl/fl^ Cre^+/−^) with no tamoxifen or in WT mice (*Igf2*^fl/fl^ Cre^−/−^) or for the recombined allele at 384 bp in iKO mice (*Igf2*^fl/fl^ Cre^+/−^) plus tamoxifen (B). qPCR for *Igf2* mRNA in choroid plexus (C) and hippocampus (D) from samples collected 2 weeks post tamoxifen administration. See also [Figure S1](#mmc1){ref-type="supplementary-material"}. Representative sections of Luxol fast blue and H&E stains at the level of the septal nuclei and the third ventricle of WT and iKO mice (E and F). Statistical significance: ^∗^p \< 0.05 using ANOVA and Tukey's post hoc test, n = 5 WT and n = 12 iKO mice. Error bars represent SEM. Scale bar, 1 mm.

To evaluate the effects of *Igf2* deletion on NSCs and progenitors in the SGZ and SVZ, we analyzed the preservation of label-retaining cells using temporally spaced administrations of the thymidine analogs iododeoxyuridine (IdU) and chlorodeoxyuridine (CldU) as depicted in [Figure 2](#fig2){ref-type="fig"}A ([@bib48], [@bib71]). Studies were performed to validate lack of cross-reactivity in detecting IdU and CldU ([Figure S2](#mmc1){ref-type="supplementary-material"}). We examined the number of IdU and CldU single- and double-positive cells in the SGZ and SVZ in the WT and iKO mice, where double analog-positive cells are the label-retaining, slowly cycling, NSCs ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Glial fibrillary acidic protein (GFAP), which is expressed by adult NSCs in SVZ and SGZ, was also included for analysis. Triple-positive IdU/CldU/GFAP cells were observed in the SGZ and SVZ, along with IdU and CldU single-positive cells ([Figures 2](#fig2){ref-type="fig"}B--2C′ and [3](#fig3){ref-type="fig"}A--3D′) but it was difficult to establish whether a cell was definitively GFAP^+^ and thymidine analog positive; therefore, GFAP expression was not included in the stereology analyses. The numbers of single- and double-positive cells for the analogs were counted using unbiased stereology ([Figures 2](#fig2){ref-type="fig"}D and [3](#fig3){ref-type="fig"}E). Significantly fewer IdU^+^/CldU^+^ cells were observed in both the SGZ ([Figure 2](#fig2){ref-type="fig"}D) and SVZ ([Figure 3](#fig3){ref-type="fig"}E) in the iKO mice compared with WT mice, consistent with an essential function for IGF-II in NSC homeostasis. Concomitant with the loss of IdU^+^/CldU^+^ cells, there was an increase in progenitors that were only CldU^+^ in the iKOs attributable to maturation of NSCs into progenitor cells ([Figures 2](#fig2){ref-type="fig"}D and [3](#fig3){ref-type="fig"}E). Using a four-color flow-cytometry panel established in the Levison lab ([@bib13], [@bib11]), we evaluated the composition of the SVZ 12 months after Cre induction. Compared with the controls there was a statistically significant reduction in the NSCs (1.27% ± 0.09% NSCs in WT versus 1.01% ± 0.07% in iKOs) with modest increases in the proportions of two progenitor cell populations ([Table 1](#tbl1){ref-type="table"}). We evaluated the extent of apoptotic death within the SVZ and SGZ using *in situ* end labeling but detected no difference between the WT and iKO mice, indicating it was unlikely that the decrease in IdU/CldU-labeled cells in the iKO mice was due to apoptotic cell death ([Figure S3](#mmc1){ref-type="supplementary-material"}).Figure 2IGF-II Maintains Label-Retaining Cells in the SGZ of the Hippocampus and Is Necessary for Learning and MemorySchematic of timeline for tamoxifen administration and labeling with IdU and CldU (A). Representative images of the hippocampi of WT (B) and iKO mice (C). Scale bars, 100 μm. IdU red, CldU green, GFAP white, and DAPI blue. (B′) and (C′) are insets from the regions marked in (B) and (C), respectively (scale bars, 20 μm). Counts of single- and double-positive cells for CldU and IdU in the SGZ (D), n = 6 WT and n = 6 iKO mice. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}. Morris water maze latency to platform in seconds (E), and probe trial (F), n = 13 WT and n = 16 iKO mice. Open field test percent time spent in center across each 5-min interval (G), and maps of typical path taken (H), n = 10 WT and n = 15 iKO mice. WT black, iKO red. Statistical significance in (D) and (F) by Student's t test (^∗^p \< 0.05) and repeated-measures ANOVA in (E) and (G) (^∗^p \< 0.05). In (E), a session effect was observed in WT mice but not in iKO mice. Error bars represent SEM.Figure 3IGF-II Is Required for SVZ NSC Maintenance, OB Neurogenesis, and OlfactionWT (A and B) and iKO (C and D) mouse SVZs stained for IdU, CldU, and GFAP; insets (with primes) are enlargements. Scale bars, 100 μm (A--D) and 20 μm (A′--D′). IdU red, CldU green, GFAP white, and DAPI blue. Counts of single- and double-positive cells for CldU and IdU within 20 μm of the lateral ventricle wall (E), n = 6 WT and n = 6 iKO mice. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}. Olfactory bulb was examined for immature neurons using doublecortin (DCX, red) and DAPI (blue) in WT (F) and iKO (G). Scale bars, = 100 μm. Fluorescence intensity was measured for DCX^+^ cells (H), n = 3 WT and n = 3 iKO mice. WT (I and K) and iKO (I′ and K′) for granule cell layer (I and I′) and periglomerular layer (K and K′) stained for BrdU and NeuN, 5 weeks after administering BrdU. Arrows indicate double-positive, newly generated neurons. Scale bars, 100 μm. Quantification of newly formed cells in the granule cell layer (J) and periglomerular cell layer (L), n = 3 WT and n = 3 iKO mice. See also [Figure S4](#mmc1){ref-type="supplementary-material"}. Paraformaldehyde fixed and decalcified preparations of mouse nasal pharynxes were embedded in paraffin and sectioned at 8 μm. Sections from WT and iKO mice were stained using PAS and visualized by light microscopy; representative sections of WT and iKO mice are provided. Scale bar, 20 μm (M). Buried food test showing latency to find food versus genotype (N), WT (black) and iKO (red), n = 5 WT and n = 6 iKO mice. Statistical significance: ^∗^p \< 0.05 and ^∗∗^p \< 0.005 using Student\'s t test, iKO versus WT. Error bars represent SEM.Table 1Multicolor Flow Cytometry Reveals a Decrease in SVZ Neural Stem Cells after *Igf2* Conditional DeletionCell TypeNSCMP1MP2GRP/MP3MP4PFMPBNAPGRP3WT1.27% ± 0.09%[a](#tblfn1){ref-type="table-fn"}18.73% ± 2.53%4.30% ± 1.30%10.33% ± 1.40%0.50% ± 0.31%0.90% ± 0.23%8.68% ± 1.90%0.34% ± 0.07%iKO1.01% ± 0.07%^∗^[b](#tblfn2){ref-type="table-fn"}21.87% ± 2.02%4.91% ± 1.46%8.33% ± 1.30%0.33% ± 0.21%1.03% ± 0.19%13.46% ± 2.30%0.38% ± 0.06%[^3][^4][^5]

Several studies have correlated increased or decreased cell proliferation in the SGZ with improvements or deficits in learning and memory, respectively (for a review see [@bib78]). Since *Igf2* deletion altered the numbers of dual nucleotide label-retaining cells and increased the number of CldU^+^ proliferating cells, we performed studies to determine whether the *Igf2* iKO mice had deficits in hippocampal function using the Morris water maze to test spatial learning and memory and the open field test to evaluate exploratory activity and anxiety ([Figures 2](#fig2){ref-type="fig"}E--2H). WT mice initially required 50 s to find the hidden platform in the Morris water maze, but quickly learned the location of the platform, and their latency to find the platform decreased from 50 s to 10 s. By contrast, the iKO mice were impaired in learning and displayed longer latencies to find the platform (repeated-measures ANOVA, n = 16 iKO and n = 13 WT) ([Figure 2](#fig2){ref-type="fig"}E). To test memory retention, we tested mice in a probe trial. WT mice swam significantly longer (50%) in the target quadrant than the iKO mice (35%) ([Figure 2](#fig2){ref-type="fig"}F). There was no difference between genotypes in the ability to find a visible platform (data not shown).

We further assessed the effects of losing IGF-II on exploratory and anxiety behavior using an open field test. Mice were placed into an open field test apparatus and were evaluated across six 5-min intervals. Overall the total distance traveled was unaltered between WT and iKO mice (data not shown). However, the iKO mice traveled less distance than the WT mice in the first two intervals (iKO 1,683 ± 121 and 1,103 ± 104 versus WT 2,072 ± 129 and 1,426 ± 94), and the total time that the iKO mice were immobile was significantly increased compared with WT mice (iKO 955.4 ± 47.7 versus WT 761 ± 64.8). What emerged most clearly across trials was that the iKO mice avoided the center of the arena ([Figures 2](#fig2){ref-type="fig"}G and 2H) (n = 13 iKO and n = 10 WT), indicating increased anxiety in the iKO mice.

One function of the NSCs in the rodent SVZ is to give rise to neuroblasts that migrate through the rostral migratory stream (RMS) to the olfactory bulb, resulting in 10,000--30,000 new neurons per day ([@bib47]). As the iKO mice had fewer IdU^+^/CldU^+^ cells but increased CldU^+^ cells in the SVZ, we performed analyses to determine whether there were increased numbers of migrating neuroblasts or new neurons in the olfactory bulb. The relative numbers of doublecortin (DCX)-positive immature neurons in the RMS entering the olfactory bulb were equivalent between the WT and iKO mice ([Figures 3](#fig3){ref-type="fig"}F--3H). However, using bromodeoxyuridine (BrdU) to label dividing progenitors in the SVZ and BrdU^+^/NeuN^+^ immunostaining to trace their differentiation into new olfactory bulb neurons, we observed a dramatic increase in the number of double-positive BrdU/NeuN cells in the granule cell layer of the olfactory bulb in the iKO mice compared with the WT mice ([Figures 3](#fig3){ref-type="fig"}I and 3J). In contrast, the number of double-positive BrdU/NeuN cells was unchanged in the iKO periglomerular layer of the olfactory bulb ([Figures 3](#fig3){ref-type="fig"}K and 3L). It has been well established that the new olfactory bulb neurons produced by the SVZ are GABAergic inhibitory interneurons ([@bib8], [@bib14], [@bib37], [@bib52], [@bib72]); however, we were unsuccessful in establishing which subset of interneurons were overproduced as neither calretinin, calbindin, nor tyrosine hydroxylase stained the BrdU^+^/NeuN^+^-labeled neurons ([Figure S4](#mmc1){ref-type="supplementary-material"}).

Using the buried food test as an olfaction assay, we found that the iKO mice took twice as long as the WT mice (iKO 325 ± 24 s versus WT 146 ± 18 s) to find a buried Fruit Loop ([Figure 3](#fig3){ref-type="fig"}N). As there are stem cells and olfactory receptor cells in the olfactory epithelium that turn over, an involution of the olfactory epithelium could explain the olfaction deficit; however, the morphology and structure of the olfactory epithelium appeared unchanged in both H&E-stained and periodic acid-Schiff (PAS)-stained sections of the iKO mice ([Figure 3](#fig3){ref-type="fig"}M). Therefore, we conclude that the loss of IGF-II led to an increase in SVZ progenitors, which in turn led to the overproduction of new inhibitory neurons in the olfactory bulb, resulting in a deficit in olfaction.

Adult ISCs Require Sustained IGF-II Production {#sec2.2}
----------------------------------------------

We next asked whether IGF-II has a broader function in maintaining other adult stem cells. We speculated that the lethality of *Igf2* iKO mice receiving five consecutive daily doses of tamoxifen might be due to a rapid loss of ISCs, whose differentiated progeny normally live for 3--5 days after cell-cycle exit ([@bib69]). To test this hypothesis, we analyzed the intestines from tamoxifen-injected iKO mice and their WT littermate controls on day 6 after tamoxifen administration. At this time, there was an average of 15% body-weight loss in iKO mice when compared with the WT littermates ([Figure 4](#fig4){ref-type="fig"}A). Analyses of the chemical composition of the plasma failed to detect consistent differences between the iKOs and WT mice; hematocrit was normal in iKOs, and no difference was detected in leukocyte frequencies (data not shown). However, iKO mice showed clear signs of declining health including hunched backs, lethargy, and reduced food/water intake (data not shown). All iKOs, if not sacrificed at this time, would die within a week. The intestinal tract of the iKO mice appeared translucently pale with dilated lumen, enlarged cecum, and no solid feces in the colonic lumen ([Figures 4](#fig4){ref-type="fig"}B--4E). These pathological effects were not due to tamoxifen toxicity, as intestines from the WT littermates subjected to the identical tamoxifen treatment appeared normal.Figure 4Loss of IGF-II Abrogates Intestinal HomeostasisFive consecutive injections of tamoxifen (75 mg/kg) were administered from day 1 to day 5 and tissues were analyzed on day 6. Body-weight curve of WT and iKO mice from day 1 to day 6 (A), n = 3 WT and n = 4 iKO mice. WT (B and D) and iKO (C and E) guts were surgically dissected (from the stomach to the colon) and the ceca were photographed at day 6. Scale bars, 6 inches for intestines and 200 μm for cecum. *Igf2* mRNA (F--G′) and IGF-II protein (I--J′) levels were detected in WT (F, F′, I, and I′) and iKO (G, G′, J, and J′) intestine using *in situ* hybridization and immunohistochemistry, respectively. Scale bars, 200 μm. n = 3 WT and n = 3 iKO mice. ^∗^p \< 0.05 by Student\'s t test. Error bars represent SEM.

*In situ* hybridization showed that *Igf2* was highly expressed in WT crypts and at lower levels in villus epithelium as well as some mesenchymal cells ([Figures 4](#fig4){ref-type="fig"}F, 4F′, and 4H). *Igf2* mRNA levels were significantly reduced in iKO intestines ([Figures 4](#fig4){ref-type="fig"}G--4H). Immunohistochemistry for IGF-II confirmed the mRNA pattern with IGF-II protein drastically reduced in iKO intestines, most notably in the crypts ([Figures 4](#fig4){ref-type="fig"}I--4K).

Histological examination suggested a clear loss of villus-crypt boundaries and a transit amplifying cell zone in iKO intestines, where the villi became severely blunted ([Figures 5](#fig5){ref-type="fig"}A--5B′). Approximately 80% of the WT crypts had robust expression of Olfm4, a marker of crypt-based columnar (CBC) stem cells ([@bib5], [@bib69]), whereas only 10% of the iKO crypts showed detectable *Olfm4* expression ([Figures 5](#fig5){ref-type="fig"}C--5E). Even when *Olfm4*^+^ crypts were occasionally found, these crypts had an abnormal morphology ([Figure 5](#fig5){ref-type="fig"}D, inset). Ki67^+^ transit amplifying cells were abundant in WT crypts but were significantly decreased in iKO crypts ([Figures 5](#fig5){ref-type="fig"}F--5H), suggesting that loss of IGF-II caused a severe reduction of transit amplifying and potentially stem/progenitor cell populations.Figure 5IGF-II Maintains the Morphology and Stemness of the Small IntestineSmall intestine of WT and iKO mice after five consecutive injections of tamoxifen (75 mg/kg) were stained and quantified for H&E (A--B′), *Olfm4* (C--E), Ki67 (F--H), and lysozyme (I--K). qPCR analyses were performed in WT and iKO intestines to detect marker genes for stem cells (L), progenitors (M), Paneth cells (N), and quiescent stem cells (O). n = 3 (WT) and 3 (iKO) mice. See also [Figure S5](#mmc1){ref-type="supplementary-material"}. Scale bars, 200 μm. ^∗^ p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 by Student\'s t test. Error bars represent SEM.

Lysozyme-positive Paneth cells were present at the bottom of the WT crypts ([Figures 5](#fig5){ref-type="fig"}I, 5I′, and 5K). In contrast, all Paneth cells were virtually eliminated from the iKO crypts ([Figures 5](#fig5){ref-type="fig"}J, 5J\', and 5K). Some lysozyme^+^ cells were seen in the iKO villi ([Figures 5](#fig5){ref-type="fig"}J \[arrowhead and inset\], 5J′, and 5K). qRT-PCR verified an overall reduction of the genes in the iKO that are characteristic of Wnt/β-catenin signaling and fast-cycling stem cells ([Figures 5](#fig5){ref-type="fig"}L and 5M), as well as Paneth cells ([Figure 5](#fig5){ref-type="fig"}N) and alternative stem cell populations ([Figure 5](#fig5){ref-type="fig"}O). These data suggested that there was a severe impairment in the crypt compartment affecting both stem and Paneth cell populations in iKO mouse intestines.

To determine whether ISCs in iKO crypts indeed lost self-renewal capacity, we isolated intestinal crypts from WT and iKO mice 5 days after tamoxifen administration *in vivo*, and cultured them in EGF, Noggin, and R-spondin-1 (ENR) medium. WT crypts underwent continuous budding ([Figure 6](#fig6){ref-type="fig"}A), whereas few iKO crypts initiated budding (arrows in [Figure 6](#fig6){ref-type="fig"}A). The percentage of viable iKO organoids was significantly reduced ([Figure 6](#fig6){ref-type="fig"}B). We then performed inducible *Igf2* deletion in culture, by adding 4-hydroxytamoxifen (4-OHT) to the iKO organoids that already formed *in vitro*. Addition of 4-OHT, but not vehicle, led to clear regression of buds in iKO organoids at day 3 (compare left and middle columns in [Figure 6](#fig6){ref-type="fig"}C). Tamoxifen-induced genomic recombination at *Igf2* locus was verified by PCR ([Figure 6](#fig6){ref-type="fig"}D). When we supplemented the ENR medium with IGF-II, such bud regression was prevented (right column in [Figure 6](#fig6){ref-type="fig"}C), even though similar recombination occurred in the organoid ([Figure 6](#fig6){ref-type="fig"}D). Counting of normal-appearing budding organoids from these cultures indicated a rescuing effect by the exogenous IGF-II protein ([Figure 6](#fig6){ref-type="fig"}E). 5-Ethynyl-2′-deoxyuridine (EdU) incorporation further suggested that 4-OHT treatment decreased numbers of the proliferative cells in epithelial buds, which was restored by IGF-II addition ([Figures 6](#fig6){ref-type="fig"}F and 6G). These data collectively demonstrate that IGF-II loss reduces the clonogenic activity of ISCs, supporting the idea that IGF-II is essential for adult ISC maintenance.Figure 6*Igf2* Knockout Impairs the Growth of Intestinal OrganoidsWT and iKO (*Igf2*^*fl/fl*^*Cre*^+/−^) organoids were cultured in medium containing EGF, Noggin, and R-spondin1 (ENR) for 5 days. Arrows delineate small organoids with few Paneth cells. Arrowhead indicates dying organoid on day 3, which was confirmed to be dead on day 5 (A). Survival curve of organoids from WT and iKO mice (B). 4-OHT or vehicle was added to iKO (*Igf2*^*fl/fl*^*Cre*^+/+^) organoid cultures at day 7. The organoids were imaged daily (C), harvested for genotyping (D), and scored daily (E). The positive control (p.c.) used in (D) is the genomic DNA sample from a Rosa26-CreER heterozygous mouse sample to show the WT (bottom) and mutant (upper) PCR products. EdU staining was performed at day 4 after 4-OHT treatment (F and G). Scale bars, 200 μm. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus controls by Student\'s t test or one-way ANOVA. Data were analyzed from n = 3 independent mice. Error bars represent SEM.

Discussion {#sec3}
==========

Taken altogether, our studies demonstrate that IGF-II is necessary for the maintenance of distinct adult epithelial stem cells in both the SVZ and SGZ of the brain and in the intestine, thus making it an essential factor for these stem cell niches. In these studies we removed *Igf2* from adult mice using two different tamoxifen dosing schemes, one time a day for 5 days or one time every 3 days across 15 days. Both dosing schemes significantly reduced levels of IGF-II; however, acutely deleting *Igf2* resulted in death of the mice and, therefore, could only be used for short-term studies and not for long-term neurogenesis studies. The stem cells and proliferating progenitors in the intestinal crypt failed to self-renew, lethally compromising the functions of the gastrointestinal tract. Within a crypt, two stem cell populations have been described: fast-cycling and quiescent stem cells, and specific markers are available for their identification. Lgr5 and Olfm4 mark the fast-cycling or CBC stem cells, whereas Hopx, Bmi1, and Lrig1 mark the quiescent stem cells ([@bib5], [@bib59], [@bib66], [@bib76]). Under certain conditions (e.g., injury, radiation), interconversion between the two stem cell populations has been reported, although the functional significance of the quiescent stem cells remains under debate given the robust expression of all quiescent stem cell markers by Lgr5^+^ cells ([@bib54], [@bib61]). When ISCs were examined using the same tamoxifen administration protocol as used to study the NSCs (five doses of tamoxifen administered every 3 days), little effect was observed. The small intestines in the iKO mice appeared normal upon gross inspection. However, there was a significant increase in the Ki67^+^ transit amplifying cell population (p \< 0.001), and a slight but nonsignificant increase in crypts with multiple Hopx^+^ cells ([Figure S5](#mmc1){ref-type="supplementary-material"}). These results suggest that slow deletion of *Igf2* allowed alternative intestinal epithelial cell populations, as we recently reported ([@bib77]), to compensate for the loss of fast-cycling stem cells, which appear to be more sensitive to IGF-II loss.

*Igf2* deletion reduced the numbers of dual nucleotide label-retaining cells and increased newly dividing cells labeled for the second nucleotide (CldU) in both the SGZ and SVZ, which correlated with behavioral deficits in the Morris water maze, open field test, and the buried food test. Our findings taken together with the prior studies by [@bib9] and [@bib25] now reveal that IGF-II regulates adult NSCs in both the SVZ and SGZ, but that distinct sources of IGF-II support these two neurogenic niches. In the SGZ/DG, *Igf2* is expressed by the NSCs themselves, and this autocrine production is likely the main source of IGF-II for the NSCs. [@bib25] demonstrated that *Igf2* deletion from the endothelial compartment has little impact on the SGZ/DG NSCs. In the SVZ, the main sources of IGF-II that regulate the NSCs likely are from both the choroid plexus and endothelial cells ([@bib25], [@bib44]). The complete deletion of *Igf2* in the adult brain in our study resulted in a reduction in the SGZ/DG and SVZ NSCs and likely contributed to the greater effect we saw on the neurogenic niches that resulted not only in a reduction in NSC numbers but also in an increase in rapidly dividing progenitors. Moreover, we observed a burst of newly generated neurons in the olfactory bulb. Whereas embryonic deletion of *Igf2* caused a reduction in NSCs in both adult niches, [@bib25] saw no concomitant increase in rapidly dividing progenitors or in newly generated neurons in the olfactory bulb in these mice or in mice with endothelial *Igf2* deletion. It is possible that the embryonic deletion of *Igf2* significantly altered the initial establishment of NSCs present in the adult SVZ, consistent with the significant reduction in brain size in these mice.

Several studies have begun to establish a link between IGF-II, memory, and cognitive impairment. For example, IGF-II in the hippocampus is necessary for memory consolidation and promotes memory enhancement ([@bib1], [@bib16]). Moreover, IGF-II is being considered as a therapeutic target for Alzheimer\'s disease ([@bib51]). Our studies demonstrating that IGF-II is required for maintenance of a subset of adult NSCs suggest that IGF-II may be important for healthy aging and that reduced levels of IGF-II that occur with aging ([@bib6], [@bib17], [@bib39]) may contribute to neurodegenerative or psychiatric diseases.

Our studies demonstrating that IGF-II also is essential for the rapidly dividing ISCs has important implications for understanding the regulation of epithelial stem cell renewal in the intestines as well as for understanding and treating colorectal cancers. The rapid deletion of *Igf2* impaired ISC homeostasis, as manifested by loss of CBCs and transit amplifying cells. This phenotype was strong in all iKO mice that received five consecutive doses of tamoxifen. The lethality and the histopathology are reminiscent of Tcf4 deletion ([@bib40], [@bib70]), conditional deletion of β-catenin ([@bib26], [@bib35]), or overexpression of secreted *Dickkopf-1*, a Wnt inhibitor ([@bib41], [@bib53]). Redundancy exists among various Wnt proteins, and there are multiple sources of Wnts in the intestinal stem cell niche ([@bib2], [@bib22], [@bib36]). In contrast, the phenotype presented here that resulted from the loss of a single growth factor, IGF-II, was striking.

LOI of *Igf2* is found commonly in many types of cancer, including colorectal cancer (CRC) ([@bib28], [@bib42], [@bib75]), and *Igf2* LOI is a potential marker for CRC risk ([@bib19]). Increased allelic *Igf2* expression promotes intestinal tumor formation and hyperproliferation of crypt epithelium with longer intestinal crypts ([@bib7], [@bib34]). Overexpression of *Igf2* shifts cells to a less differentiated state, resulting in increased tumor initiation rather than proliferation ([@bib58]). Insulin receptor substrate 1 (IRS-1), which is an intracellular mediator of both insulin and the IGF actions, has been implicated as an important determinant for ISC survival after injury, and partial or absolute IRS-1 deficiency in mice carrying the Apc^min/+^ mutation led to reduced tumor number relative to IRS-1^+/+^/Apc^min/+^ mice. Furthermore, elevated levels of insulin correlate with both low intestinal epithelial cell apoptosis and increased adenoma risk ([@bib38], [@bib55]).

Our prior published studies indicate that IGF-II promotes SVZ NSC stemness *in vitro* through the A splice isoform of the insulin receptor and independently of either the IGF type 1 receptor (IGF-1R) or IGF-2R ([@bib80], [@bib79]). Interestingly, the recent study by [@bib9] showed that IGF-II acted through the IGF-1R to support DG/SGZ NSCs. Thus, IGF-II may have specific effects on the two neurogenic niches through distinct receptors to promote cell regeneration and healthy aging. While structurally similar, the differences in the biological effects of IGF-I and IGF-II are significant, and our studies demonstrate that much more needs to be learned about IGF-II and how it signals through its cognate receptors to affect specific adult stem cell populations.

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

All experiments were performed in accordance with protocols approved by the institutional animal care and use committee of Rutgers-New Jersey Medical School and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised in 1996. Mouse strains included Cre^ER^ driven off a Gt(*ROSA*)26Sor promoter (Gt(ROSA)26Sor^tm1(cre/Esr1)Nat/^J) (Jax mouse stock \#004847) and floxed *Igf2* mice ([@bib33]). Mice were obtained as C57BL/6 mixed strain and were backcrossed for five generations onto C57BL/6 (Jackson Laboratory) prior to use. Male and female mice, heterozygous for Cre, Gt(ROSA)26Sor^tm1(cre/Esr1)Nat/^J and homozygous for floxed *Igf2* were bred to generate mice used for the experiments. Progeny from the cross consisted of either heterozygous or homozygous Cre with homozygous floxed *Igf2* (iKO) and homozygous floxed *Igf2* mouse littermates that did not carry the Cre (WT).

Tamoxifen and Nucleotide Administration {#sec4.2}
---------------------------------------

Both Cre^+^ (iKO) and Cre^−^ (WT) mice were administered tamoxifen (Sigma T5648; 75 mg/kg) intraperitoneally beginning at 4--5 weeks of age according to the schedule in [Figure 1](#fig1){ref-type="fig"} for the NSC analyses or over 5 consecutive days for the intestinal analyses. For the NSC analysis, mice were 54 days old (±5 days) at the start of dual analog labeling and approximately 6 months old at tissue collection, and were the same across genotypes. A distinct cohort of mice between the ages of 2.5 and 6 months were used for behavioral studies. For the ISC analyses, mice were used 5--6 days following administration of tamoxifen.

Thymidine Analog Detection {#sec4.3}
--------------------------

IdU (Sigma I7125) or BrdU (Sigma, B5002) were provided at 1 mg/mL in 1% sucrose water. CldU (Sigma C-6891), dissolved in 0.9% saline, was administered intraperitoneally at 42.5 mg/kg. IdU and CldU detection was performed as described by [@bib68]. GFAP (DAKO 1:500) was also included for analysis. IdU was detected with Dylight 549 conjugated secondary antibody, CldU with Dylight 488 conjugated secondary antibody, and GFAP with an Alexa 647 conjugated secondary antibody (all from Jackson ImmunoResearch) along with 4′,6′-diamidino-2-phenylindole (DAPI) at 1:1,000 in PBS for 15 min. Slides were coverslipped using Fluorogel (Electron Microscopy Sciences, \#19440).

Stereology {#sec4.4}
----------

For stereology analysis, 8-μm adjacent hippocampal or 5-μm adjacent SVZ tissue sections stained with CldU/IdU/GFAP/DAPI were used. Cell counts were performed using the physical fractionator (StereoInvestigator; MBF Bioscience). A systematic random sampling of cells within the regions of interest in adjacent sections was performed bidirectionally to obtain an unbiased estimate of the number of single-, double-, and triple-labeled cells. Sections were coded to ensure blinding during image acquisition and counting.

DCX, NeuN, and *In Situ* End Labeling Staining {#sec4.5}
----------------------------------------------

DCX staining was performed using a goat polyclonal anti-DCX (1:100, Santa Cruz Biotechnology SC 8066) as previously described ([@bib74]). The relative fluorescence intensity of DCX-positive cells was quantified using ImageJ software. Sections were stained for BrdU and NeuN as described previously ([@bib30]). *In situ* end labeling was performed as described previously ([@bib57]). Images were taken using a Q-imaging mono 12-bit camera interfaced with iVision 4 scientific imaging software (Scanalytics).

For multicolor flow cytometry, WT and iKO mice were administered tamoxifen (75 mg/kg) every 3 days beginning at 4--5 weeks of age and were euthanized at 12 months of age. SVZ cells were dissociated and stained using fluorescently labeled probes to the following cell-surface antigens: CD133/LeX/NG2/CD140a. A total of 50,000 cell events were analyzed per animal after excluding debris and dead cells by DAPI. A two-gate strategy was used to group cells into one of eight categories.

Behavioral Tests {#sec4.6}
----------------

Mice were tested for alterations in olfaction using a buried food test as described by [@bib73]. Deficits in hippocampal function were determined using the Morris water maze to test spatial learning and memory and the open field test to evaluate exploratory activity and anxiety (for a review see [@bib78]). Details of these procedures can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Intestinal Tissue Analyses {#sec4.7}
--------------------------

Small intestines were dissected and flushed with cold PBS. The proximal halves were fixed in DEPC-treated 4% paraformaldehyde for 1 h at room temperature, changed into 30% sucrose overnight at 4°C, frozen, and sectioned at 10 μm for *in situ* hybridization. The distal halves were fixed in 4% paraformaldehyde overnight, embedded in paraffin, and sectioned at 5 μm for immunohistochemistry. *In situ* hybridization analysis for *Igf2* and *Olfm4* was performed as previously described ([@bib31], [@bib32]). Paraffin sections were stained with H&E, for lysozyme (1:8, Biogenex), Ki67 (1:2000, Vector Laboratories), and Hopx (1:1,000, Santa Cruz). Frozen tissue sections were stained for IGF-II (1:1,000, Santa Cruz) as previously described ([@bib27]). For *Igf2 in situ* hybridization and IGF-II immunohistochemistry, individual crypts were visually scored, based on staining intensities, into none, weak, and strong categories. Percentage of each category was presented in results. For Olfm4 *in situ*, crypts with positive Olfm4 staining were manually counted and reported from sections of intestinal tissues. For Ki67, lysozyme, and EdU staining, numbers of positive cells were counted for individual crypts and reported as the average number per crypt. For Hopx, percentages of crypts containing 1, 2, or 0 strongly Hopx-positive cells were reported. All values are presented as means ± SEM. Differences among groups were analyzed by Student's t test with GraphPad Prism version 5.01. Significance was noted when p was less than 0.05.

Intestinal Organoid Culture {#sec4.8}
---------------------------

Organoids were derived from isolated crypts of the proximal small intestine of WT and iKO mice as described previously ([@bib60], [@bib62]). Organoids were maintained in an ENR-containing medium. Organoid growth was imaged and quantified by scoring the number of live organoids that developed during the 5 days after isolation or treatment. For *in vitro* induction of *Igf2* deletion, organoids were derived and cultured as above from iKO (*Igf2*^*fl/fl*^*Cre*^+/+^) mice and were treated for 12 h with either 0.5 μM 4-OHT (iKO) or vehicle on day 7 as described previously ([@bib22]). EdU (Life Technologies) staining was performed according to the manufacturer\'s instructions. Data were analyzed from organoids isolated from three independent mice.
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[^1]: Co-first author

[^2]: Co-senior author

[^3]: See also [Figure S3](#mmc1){ref-type="supplementary-material"}. NSC, neural stem cell; MP1, multipotential 1; MP2, multipotential 2; MP3/GRP2, multipotential 3/glial restricted progenitor 2; PFMP, PDGF- and FGF-responsive multipotential progenitors; BNAP/GRP1, bipotential neuronal-astrocytic precursor/glial restricted progenitor 1; GRP3, glial restricted progenitor 3; WT, wild-type; iKO, inducible KO.

[^4]: Data are presented as mean values ± SEM, n = 17 WT and 19 iKO mice of both sexes.

[^5]: ^∗^p \< 0.05 by one-way ANOVA and Tukey\'s post hoc test.
